The US FDA insists on efficacy. The Johnson & Johnson vaccine, a single-dose injection, can prevent COVID-19 infection by 66%. Prepare to distribute the vaccine As soon as approved
Faculty of Science And experts The US Food and Drug Administration (FDA), or the US FDA, confirmed that the COVID-19 vaccine developed by Johnson & Johns subsidiary Janssen Pharmaceutical Nonson (J&J), the daily drug and commodity giant, has just one dose effective against COVID-19 infection. In moderate to severe severity at 66 percent.
The results of the J&J vaccine review raised hope that It will effectively stop the outbreak of the deadly virus in the United States. Because using just one dose It is safe to use. More importantly, it also increases protection against infection with mutants. Which was previously believed to be able to suppress COVID-19 Brazilian species Up to 68 percent and South Africa’s COVID-19 strains at 64 percent
Assessment process And make the final decision Of the Independent Advisory Council before the FDA Will consider approving the use of the said vaccine It is an emergency, it may happen as soon as possible. Tomorrow (Feb. 26) local time.
Mr. Jeff Zeents, COVID-19 Coordinator The White House said that if the J&J vaccine is approved, Authorities will be able to allocate 3-4 million doses of the vaccine within the next week, with J&J contracting the federal government that It will produce 100 million doses of the vaccine by June. And the company is working to accelerate production
Efforts to advance the COVID vaccination program in the US have not met the deadline. After confronting the weather problem And transportation, leading to a significant delay in the vaccination program.
So far, 65 million Americans have received the vaccine made by Pfizer. And biotech Or at least one dose of Moderna, in which this group needs to receive a second dose of vaccine to be able to protect against the virus effectively.
For J&J clinical trials in 44,000 volunteers in the United States, Latin America and South Africa. The vaccine was found to inhibit COVID-19. In the United States, the highest at 72 percent, compared with defense efficiency in Latin America at 66 percent and South Africa at 57 percent.
Despite the difference Which is in accordance with the severity of the virus strain But the results of the J&J single dose of the vaccine are high. It is also a test in patients with severe symptoms. And previous studies have also found no reports of admission or death 28 days after vaccination.
Read more news
SHARE
FOLLOW US
–
